Ionis Pharmaceuticals (IONS) Common Equity (2009 - 2026)

Ionis Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $491.4 million for Q1 2026.

• On a quarterly basis, Common Equity rose 3.3% year-over-year to $491.4 million in Q1 2026; TTM through Mar 2026 was $491.4 million, a 3.3% increase from a year earlier, with the FY2025 full-year figure at $489.1 million, down 16.87% from the prior year.
• Common Equity held at $491.4 million in Q1 2026 per IONS's latest filing, from $489.1 million in the prior quarter.
• Across five years, Common Equity topped out at $709.6 million in Q1 2022 and bottomed at $263.7 million in Q2 2024.
• The 5-year median for Common Equity is $491.4 million (2026), against an average of $508.0 million.
• Across the five-year window, Common Equity tumbled 46.92% in 2023 and surged 139.56% in 2025, its largest moves.
• Year by year, Common Equity stood at $572.9 million in 2022, then tumbled by 32.5% to $386.7 million in 2023, then soared by 52.15% to $588.4 million in 2024, then fell by 16.87% to $489.1 million in 2025, then grew by 0.48% to $491.4 million in 2026.
• Per Business Quant, the three latest IONS Common Equity figures stand at $491.4 million (Q1 2026), $489.1 million (Q4 2025), and $618.0 million (Q3 2025).